Vertex Pharmaceuticals Inc (VRTX)
402.18
+9.37
(+2.39%)
USD |
NASDAQ |
May 01, 16:00
401.18
-1.00
(-0.25%)
After-Hours: 05:02
Vertex Pharmaceuticals Research and Development Expense (TTM): 3.163B for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.163B |
| September 30, 2023 | 3.032B |
| June 30, 2023 | 2.867B |
| March 31, 2023 | 2.682B |
| December 31, 2022 | 2.540B |
| September 30, 2022 | 2.414B |
| June 30, 2022 | 2.236B |
| March 31, 2022 | 2.085B |
| December 31, 2021 | 1.940B |
| September 30, 2021 | 1.838B |
| June 30, 2021 | 1.865B |
| March 31, 2021 | 1.837B |
| December 31, 2020 | 1.830B |
| September 30, 2020 | 1.843B |
| June 30, 2020 | 1.905B |
| March 31, 2020 | 1.864B |
| December 31, 2019 | 1.754B |
| September 30, 2019 | 1.712B |
| June 30, 2019 | 1.487B |
| March 31, 2019 | 1.445B |
| December 31, 2018 | 1.416B |
| September 30, 2018 | 1.285B |
| June 30, 2018 | 1.410B |
| March 31, 2018 | 1.362B |
| December 31, 2017 | 1.325B |
| Date | Value |
|---|---|
| September 30, 2017 | 1.266B |
| June 30, 2017 | 1.084B |
| March 31, 2017 | 1.065B |
| December 31, 2016 | 1.048B |
| September 30, 2016 | 1.109B |
| June 30, 2016 | 1.083B |
| March 31, 2016 | 1.036B |
| December 31, 2015 | 995.92M |
| September 30, 2015 | 887.20M |
| June 30, 2015 | 831.86M |
| March 31, 2015 | 832.49M |
| December 31, 2014 | 855.51M |
| September 30, 2014 | 892.50M |
| June 30, 2014 | 921.01M |
| March 31, 2014 | 918.98M |
| December 31, 2013 | 898.45M |
| September 30, 2013 | 832.82M |
| June 30, 2013 | 813.54M |
| March 31, 2013 | 787.63M |
| December 31, 2012 | 765.90M |
| September 30, 2012 | 779.51M |
| June 30, 2012 | 768.40M |
| March 31, 2012 | 745.46M |
| December 31, 2011 | 707.71M |
| September 30, 2011 | 690.16M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
1.487B
Minimum
Jun 2019
3.163B
Maximum
Dec 2023
2.152B
Average
1.905B
Median
Jun 2020
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 4.784B |
| Eli Lilly and Co | 9.851B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Alpine Immune Sciences Inc | 80.90M |
| Moderna Inc | 4.845B |